Regulatory Approval

Regulatory Approval

Eco Animal Health Group Plc

9 January 2017

ECO Animal Health Group plc
(AIM: EAH)

ECO RECEIVES MEXICAN MARKETING AUTHORISATION FOR AIVLOSIN® FOR CHICKENS LAYING EGGS FOR HUMAN CONSUMPTION

ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health de México has received a marketing authorisation from the Secretariat of Agriculture, Livestock, Rural Development, Fisheries and Food (SAGARPA) of the Government of Mexico for the use of Aivlosin® 625 mg/g water soluble granules in chickens laying eggs for human consumption.

This approval, the first in Latin America following the European approval in June 2016, will allow ECO to start selling Aivlosin® in Mexico for the medication of drinking water for the treatment of infections caused by Mycoplasma in poultry laying eggs for human consumption with a zero day drug withdrawal period for eggs.

Aivlosin^®, ECO’s patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.

Peter Lawrence, Chairman of ECO, commented “This approval from the Mexican authorities is an important step in the development of Aivlosin® for commercial layers with Mexico being the world’s fourth largest egg producing country. ECO has begun the process of submitting the Aivlosin® regulatory files for the treatment of layers in numerous other key egg producing markets. It underlines ECO’s continued commitment to being a major force in the international market for veterinary pharmaceutical products.”

Contacts:

ECO Animal Health Group plc

Peter Lawrence	Â	020 8336 6190
Marc Loomes		020 8447 6906
Spiro Financial
Anthony Spiro		020 8336 6196
Peel Hunt LLP (Nominated Adviser)
Dan Webster, Adrian Trimmings, George Sellar		020 7418 8900
N+1 Singer (Joint Broker)		020 7496 3000
Mark Taylor, Brough Ransom

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170108005007/en/